Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
PubMed Central PMCID: PMC3587237
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT
PF-670462 2HCl
Robarge KD
6 logs after 48 hours from a single 100 mg) dosefollowing a single dose in patients chronically infected with HCV genotype 1
AZD3759 - CAS# 1626387-80-1 Catalog No.:M6469-10 PubMed Central PMCID: PMC3587237AZD3759, CAS No. 1626387 80 1, is also known as zorifertinib. It is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR overexpressing cells. EGFR,
US$ 427.98
US$ 170.88
US$ 1591.03
US$ 8175.80
US$ 158.50
US$ 183.20
US$ 33538.00
US$ 323.00
US$ 161.60
US$ 142.47
US$ 209.47